<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Publication:
Four years on: pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024)

Loading...
Thumbnail Image

Departments

School / College / Institute

Item type:Organizational Unit,
SCHOOL OF MEDICINE
Upper Org Unit
Item type:Organizational Unit,

Program

Organization Authors

Co-Authors

Jokubaitis, Vilija G.

Alroughani, Raed

Eichau, Sara

Hughes, Stella

Willekens, Barbara

Horakova, Dana

Havrdova, Eva Kubala

Ozakbas, Serkan

Boz, Cavit

Habek, Mario

Date

Language

Embargo Status

No

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Background: Family planning is an important aspect of multiple sclerosis (MS), and neuromyelitis optica spectrum disorder (NMOSD) management. Knowledge gaps remain, including optimal perinatal management strategies, and fetal risks associated with disease-modifying therapy (DMT) exposure.Objective: To describe perinatal DMT use, together with pregnancy and neonatal outcomes prospectively recorded in the International MSBase Pregnancy and Women's Health Registry.Methods: We report summary statistics for data collected between May 2020 and August 2024.Results: A total of 1887 relapsing-remitting MS (RRMS), 12 primary-progressive MS (PPMS), 2 radiologically isolated syndrome (RIS) and 21 NMOSD completed pregnancies were recorded, including 1644 (85.5%) live births, 208 (10.8%) miscarriages, and 6 (0.3%) neonatal deaths. Most women had unassisted (53.8%) or assisted (7.4%) vaginal births. Seventy five percent of pregnancies had DMT exposures within 6 months preconception; 19% of NMOSD, and 62% of MS pregnancies were DMT-exposed during gestation; 18.1% of pregnancies reported in-pregnancy monoclonal antibody DMT exposure. No overt safety signals were seen.Conclusion: This first report from the newly launched MSBase pregnancy registry, establishes an increasing number of pregnancies being conceived on monoclonal antibody therapies. Although no safety signals were observed, it is important to continue monitoring for safety signals in real-world databases as the use of highly effective therapies continues to increase perinatally.

Source

Publisher

Sage Publications Ltd

Citation

item.page.haspartof

Source

Multiple Sclerosis Journal

item.page.ispartofseries

item.page.edition

DOI

10.1177/13524585251349125

item.page.datauri

item.page.link

Rights

CC BY (Attribution)

Copyrights Note

Creative Commons license

Except where otherwise noted, this item's license is described as CC BY (Attribution)

Endorsement

Review

Supplemented By

Referenced By

Related Patent

Related Goal

Google Scholar
Scholar'da Ara ↗
Altmetric
Dimensions
PlumX Metrikleri
BIP! Indicators